Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.54 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531036 | 0.87 | CYP19A1 (0.51) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13524699 | 0.84 | CYP19A1 (0.55) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13530998 | 0.80 | CYP19A1 (0.60) | CYP19A1UGT1A4PDE4DESR1STS | |
| Bromide SCHEMBL8072708 | 0.78 | CYP19A1 (0.58) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13524700 | 0.76 | CYP19A1 (0.50) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13529283 | 0.76 | CYP19A1 (0.55) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13529281 | 0.75 | CYP19A1 (0.54) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13524702 | 0.74 | CYP19A1 (0.53) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13529282 | 0.73 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13524698 | 0.72 | CYP19A1 (0.51) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | CYP19A1 2832/4885UGT1A4 2631/4885PDE4D 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.